{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:36:10Z","timestamp":1794332170479,"version":"4.9.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.xcrm.2024.101571","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T11:04:31Z","timestamp":1716289471000},"page":"101571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacodynamic changes in tumor and immune cells drive iberdomide\u2019s clinical mechanisms of activity in relapsed and refractory multiple myeloma"],"prefix":"10.1016","volume":"5","author":[{"given":"Michael","family":"Amatangelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1524-6156","authenticated-orcid":false,"given":"Erin","family":"Flynt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Stong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradipta","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Van Oekelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Maciag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W.C.J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjan","family":"Thakurta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101571_bib1","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.xcrm.2024.101571_bib2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101571_bib3","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.xcrm.2024.101571_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101571_bib5","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101571_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101571_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.xcrm.2024.101571_bib8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101571_bib9","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.18632\/oncotarget.27973","article-title":"Developing next generation immunomodulatory drugs and their combinations in multiple myeloma","volume":"12","author":"Thakurta","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2024.101571_bib10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T\u00a0cells by inducing degradation of T\u00a0cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2024.101571_bib11","article-title":"Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities","volume":"10","author":"Yamamoto","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2024.101571_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma","volume":"137","author":"Gooding","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/leu.2013.315","article-title":"Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy","volume":"28","author":"Thakurta","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101571_bib14","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bjh.12291","article-title":"Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease","volume":"161","author":"Egan","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.xcrm.2024.101571_bib16","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.3324\/haematol.2017.186601","article-title":"Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients","volume":"103","author":"Franssen","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2024.101571_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1182\/blood.V128.22.120.120","article-title":"Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial","volume":"128","author":"Neri","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib18","first-page":"1754","article-title":"A Molecular Analysis of Cereblon-Related Immunomodulatory Drug Resistance in Commpass Multiple Myeloma Patients","volume":"130","author":"Skerget","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib19","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1182\/blood.2022015909","article-title":"Loss Of COP9-Signalosome Genes At 2q37 Is Associated With IMiD Agent Resistance In Multiple Myeloma","volume":"140","author":"Gooding","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101571_bib21","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib22","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.2022016212","article-title":"Thakurta A.Location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of high-risk NDMM patients","volume":"141","author":"Stong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood.2022017010","article-title":"Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed\/refractory myeloma","volume":"141","author":"Ansari-Pour","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev.immunol.15.1.155","article-title":"The role of the Ikaros gene in lymphocyte development and homeostasis Annual Review of Immunology","volume":"15","author":"Georgopoulos","year":"1997","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101571_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2017.11.005","article-title":"The Ikaros family in lymphocyte development","volume":"51","author":"Heizmann","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2024.101571_bib26","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets","volume":"125","author":"Sehgal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/cei.12343","article-title":"Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients","volume":"177","author":"Busch","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.xcrm.2024.101571_bib29","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.3109\/10428194.2014.900765","article-title":"The impact of long-term lenalidomide exposure on the cellular composition of bone marrow","volume":"55","author":"Brioli","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.xcrm.2024.101571_bib30","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00262-016-1861-2","article-title":"Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory\/relapsed multiple myeloma","volume":"65","author":"Lee","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2024.101571_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060186","article-title":"Re-Evaluation of PD-1 Expression by T Cells as a Marker for Immune Exhaustion during SIV Infection","volume":"8","author":"Hong","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101571_bib32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2024.101571_bib33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib34","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101571_bib35","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/1521-4141(200203)32:3<720::AID-IMMU720>3.0.CO;2-P","article-title":"Ikaros is critical for B cell differentiation and function","volume":"32","author":"Kirstetter","year":"2002","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.xcrm.2024.101571_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1015372322419","article-title":"Aiolos and Ikaros: Regulators of lymphocyte development, homeostasis and lymphoproliferation","volume":"7","author":"Schmitt","year":"2002","journal-title":"Apoptosis"},{"key":"10.1016\/j.xcrm.2024.101571_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1271807","article-title":"Immunomodulation of NK, NKT and B\/T cell subtypes in relapsed\/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival","volume":"13","author":"Prabhala","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2024.101571_bib38","article-title":"Iberdomite increases innate and adaptive immune cell subsets in the bone marrow of relapsed\/refractory multiple myeloma patients","volume":"5","author":"Van Oekelen","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.xcrm.2024.101571_bib39","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1182\/blood-2022-157987","article-title":"Synergistic Antitumor Activity of Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1\u00a0T Cell Engager (TCE), and Celmod Agents in Multiple Myeloma (MM) Preclinical Models","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib40","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S2152-2650(23)01793-7","article-title":"P-175 Improving Anti-BCMA CAR-T functionality with novel immunomodulatory agent Iberdomide (CC220) in Multiple Myeloma","volume":"23","author":"Aleman","year":"2023","journal-title":"Clin. Lymphoma, Myeloma\u00a0& Leukemia"},{"key":"10.1016\/j.xcrm.2024.101571_bib41","first-page":"1","article-title":"Iberdomide increased the potency of the anti-BCMA CAR T Cell product Orvacabtagene autoleucel (orva-cel)","volume":"28","author":"Soni","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101571_bib42","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2023-189423","article-title":"Iberdomide Enhances Dara Mediated Cytotoxicity through Upregulation of CDC Activity and Elevated NK Cell Mediated ADCC","volume":"142","author":"Ma","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.972021","article-title":"Roles of CD4+ T\u00a0cells as mediators of antitumor immunity","volume":"13","author":"Kravtsov","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101571_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99048","article-title":"Glioblastoma-targeted CD4+ CAR T\u00a0cells mediate superior antitumor activity","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2024.101571_bib45","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/blood-2006-10-051318","article-title":"CD4 cells can be more efficient at tumor rejection than CD8 cells","volume":"109","author":"Perez-Diez","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101571_bib46","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T\u00a0cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101571_bib47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T\u00a0cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in\u00a0vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101571_bib48","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T\u00a0cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101571_bib49","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-20-1781","article-title":"Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed\/Refractory Multiple Myeloma","volume":"26","author":"Pierceall","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101571_bib50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101571_bib51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2024.101571_bib52","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/bioinformatics\/btq559","article-title":"Robust relationship inference in genome-wide association studies","volume":"26","author":"Manichaikul","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101571_bib53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","article-title":"Use of Ranks in One-Criterion Variance Analysis","volume":"47","author":"Kruskal","year":"1952","journal-title":"J.\u00a0Am. Stat. Assoc."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124002635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124002635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T11:14:20Z","timestamp":1718709260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124002635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2666379124002635"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101571","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic changes in tumor and immune cells drive iberdomide\u2019s clinical mechanisms of activity in relapsed and refractory multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101571"}}